🇺🇸 FDA
Pipeline program

UTAA09 injection

UCART-19-002

Phase 1 mab active

Quick answer

UTAA09 injection for Recurrent or Refractory B-cell Non Hodgkin's Lymphoma is a Phase 1 program (mab) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
First Tracks Biotherapeutics
Indication
Recurrent or Refractory B-cell Non Hodgkin's Lymphoma
Phase
Phase 1
Modality
mab
Status
active

Clinical trials